TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Oct 05, 2022 19:55 JST
Source:
AIM Vaccine Co., Ltd.
AIM Vaccine Announces Global Offering Results, Offer Price of HK$16.16 per H Share
To Commence Trading on the Main Board of the Hong Kong Stock Exchange on 6 October 2022
HONG KONG, Oct 05, 2022 - (ACN Newswire) - AIM Vaccine Co., Ltd. ("AIM Vaccine" or the "Company", together with its subsidiaries, the "Group", stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), today announced the allotment results of its Global Offering. The Offer Price is HK$16.16 per H share. Dealings in the H shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") are expected to commence on 6 October 2022 (Thursday) in board lot of 200 H shares each.
The H shares initially offered under the International Offering were over-subscribed. The net proceeds from the Global Offering are intended for advancing R&D of vaccine candidates and continuing to enrich vaccine pipeline, funding the capital expenditure on the construction of new production facilities for new vaccine products, and investing in sales and marketing activities. The Company said, through one decade of organic growth and external resource integration, AIM Vaccine has become a major player in the Chinese vaccine industry. The official listing on the Hong Kong Stock Exchange marks an important milestone in the history of the development of AIM Vaccine, opening a new chapter for the Company's development. The successful listing shows the trust and support of global investors for the Company's business development, and lays a firm ground for the Company's long-term growth. Looking forward, AIM Vaccine will carry on accelerating the R&D and commercialization process of the pipeline of vaccine candidates, and become a world-class vaccine company, thereby continuing to create greater value for shareholders.
Source: AIM Vaccine Co., Ltd.
Sectors: BioTech, Healthcare & Pharm
Copyright ©2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
AIM Vaccine, a Major Player in the Chinese Vaccine Industry, Successfully Listed on the Main Board of SEHK
October 06 2022 19:16 JST
AIM Vaccine Announces Proposed Listing on the Main Board of SEHK
September 23 2022 17:06 JST
Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance
January 12 2022 10:26 JST
More Press release >>
Latest Press Release
Mitsubishi Shipbuilding Completes Handover of WAKASHIO MARU Training Ship for National Institute of Technology, Toyama College
Mar 13, 2026 16:01 JST
Mitsubishi Heavy Industries to Introduce 10MW-Class Centrifugal Chiller for Next-Generation AI Data Centers in North America
Mar 13, 2026 14:10 JST
Spritzer Sparkling's 'Serikan Raya, Sparkling-kan Suasana' Festive Fusion Message Promotes Togetherness and Tradition with a Light, Modern Twist
Mar 13, 2026 12:45 JST
Hitachi to deliver the world's first 550 kV gas-insulated switchgear in which the entire equipment is SF(6)-free to Chubu Electric Power Grid
Mar 12, 2026 19:40 JST
Honda Announces Losses Associated with Reassessment of Automobile Electrification Strategy; Revision to Forecast for Consolidated Financial Results; and Future Direction
Mar 12, 2026 19:02 JST
Japantastics Introduces the World of Kodaimoji, Bringing Ancient Characters into Modern Spaces
Mar 12, 2026 19:00 JST
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
Mar 12, 2026 17:21 JST
NEC Develops Physical AI That Anticipates Human Movement and Psychological States
Mar 12, 2026 16:41 JST
NEC and The University of Tokyo calculate carbon accumulation rates in Malaysian national park with a 9.4% margin of error
Mar 12, 2026 12:02 JST
Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY(R) in Mainland China, Addressing Unmet Need in Moderately to Severely Active Ulcerative Colitis
Mar 11, 2026 20:15 JST
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
Mar 11, 2026 12:07 JST
Fujitsu launches Japan's first defense tech open innovation program
Mar 10, 2026 11:45 JST
Fujitsu and DT-Axis collaborate to advance digital health
Mar 09, 2026 13:32 JST
Hong Kong Completes First Green Methanol Bunkering, Driving Green Transformation of Its International Shipping Hub
Mar 08, 2026 16:05 JST
International Women's Day: Why Menopause May Be a Missed Cardiovascular Risk Window
Mar 06, 2026 20:00 JST
TANAKA Develops World's First High-Performance Palladium Hydrogen Permeable Membrane Exhibiting High Hydrogen Purification Performance at Temperatures around 100 degrees C
Mar 05, 2026 22:00 JST
Honda to Begin Sales of Two U.S.-built Vehicles in Japan
Mar 05, 2026 16:47 JST
DOCOMO's New Haptic-sharing System Enables Fans to Feel Closer to Idols
Mar 05, 2026 16:38 JST
TANAKA Establishes Transfer Technology for its Sintered Gold (Au) Bonding Technology, AuRoFUSE(TM) Preforms
Mar 03, 2026 22:00 JST
Fujitsu and BCN Port Innovation Foundation leverage ocean digital twin technology to drive the regeneration of the Port of Barcelona
Mar 03, 2026 21:00 JST
More Latest Release >>